This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liistro, F. Articles by Bolognese, L. Search for Related Content PubMed PubMed Citation Articles by Liistro, F. Articles by Bolognese, L.

Effectiveness and Safety of Sirolimus Stent Implantation for Coronary In-Stent Restenosis

The TRUE (Tuscany Registry of Sirolimus for Unselected In-Stent Restenosis) Registry

Francesco Liistro, MD^_*,_*, Massimo Fineschi, MD, Paolo Angioli, MD^_*, Giuseppe Sinicropi, MD, Giovanni Falsini, MD^_*, Tommaso Gori, MD, Kenneth Ducci, MD^_*, Achille Bravi, MD and Leonardo Bolognese, MD^_*

^_* Cardiovascular Departments of San Donato Hospital, Arezzo, Italy
Le Scotte Hospital, Siena, Italy

View larger version (7K): [in a new window]   Figure 1 Cumulative distribution of late loss at angiographic follow-up. Restenosis and ischemia-driven target lesion revascularization (TLR) is reported corresponding to the respective late loss value for each lesion.

View larger version (14K): [in a new window]   Figure 2 (A) Kaplan-Meier analysis for 9-month major adverse cardiac event (MACE)-free survivals in diabetic and nondiabetic patients. (B) Kaplan-Meier analysis for survivals free from 9-month ischemia-driven target lesion revascularization (TLR) in diabetic and nondiabetic patients.

View larger version (13K): [in a new window]   Figure 3 (A) Kaplan-Meier analysis for 9-month major adverse cardiac event (MACE)-free survivals in patients with non–ST-segment elevation acute coronary syndrome (NSTEACS) and in those with stable angina. (B) Kaplan-Meier analysis for survivals free from 9-month ischemia-driven target lesion revascularization (TLR) in NSTEACS patients and in those with stable angina.